Keros Therapeutics (NASDAQ:KROS) Trading Down 3.7% – Here’s Why

Keros Therapeutics, Inc. (NASDAQ:KROS) fell 3.7% during mid-day trading on Thursday . The company traded as low as $20.13 and last traded at $20.0680. 63,757 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 934,736 shares. The stock had previously closed at $20.83.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Wedbush raised their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Wells Fargo & Company decreased their price target on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday. Finally, Bank of America boosted their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $21.38.

Keros Therapeutics Stock Down 3.6%

The company has a 50 day moving average of $17.19 and a 200 day moving average of $15.53. The stock has a market capitalization of $612.14 million, a price-to-earnings ratio of 13.02, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.93. The business had revenue of $14.26 million for the quarter, compared to analyst estimates of $4.22 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business’s quarterly revenue was up 3585.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.41) EPS. On average, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Corebridge Financial Inc. raised its holdings in shares of Keros Therapeutics by 6.4% in the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock valued at $165,000 after buying an additional 972 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock valued at $166,000 after purchasing an additional 988 shares in the last quarter. UBS Group AG raised its holdings in Keros Therapeutics by 1.1% in the third quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after purchasing an additional 1,091 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after acquiring an additional 1,888 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its position in shares of Keros Therapeutics by 29.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after purchasing an additional 1,892 shares during the period. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.